Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis
Background Pembrolizumab and atezolizumab have recently been approved for the first-line
treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for …
treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for …
Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial …
TPS589 Background: In patients (pts) with metastatic unresectable urothelial cancer,
platinum-based chemotherapy remains the standard of care for first-line treatment followed …
platinum-based chemotherapy remains the standard of care for first-line treatment followed …
Systematic literature review and meta-analysis of response to first-line therapies for advanced/metastatic urothelial cancer patients who are cisplatin ineligible
T Freshwater, H Li, C Valiathan, M Li… - American Journal of …, 2019 - journals.lww.com
Objective: The purpose of this systematic literature review (SLR) and meta-analysis was to
compile the response of historic treatment options in first-line settings for patient populations …
compile the response of historic treatment options in first-line settings for patient populations …
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).
4591 Background: EV-302 and CheckMate 901 demonstrated significant survival benefit
with enfortumab vedotin-pembrolizumab (EVPembro) and gemcitabine-cisplatin-nivolumab …
with enfortumab vedotin-pembrolizumab (EVPembro) and gemcitabine-cisplatin-nivolumab …
[HTML][HTML] Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
J Hoffman-Censits, JE Rosenberg, M van Der Heijden… - Annals of …, 2019 - Elsevier
Background In this study, we investigated whether outcomes with atezo (anti–PD-L1)
monotherapy in mUC varied between women and men across Phase (Ph) 1-3 trials in …
monotherapy in mUC varied between women and men across Phase (Ph) 1-3 trials in …
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder
NH Chakiryan, DD Jiang, KA Gillis, E Green… - … Oncology: Seminars and …, 2022 - Elsevier
Background Clinical trials have not shown a significant overall survival (OS) difference
between chemotherapy and immunotherapy as first-line agents in metastatic urothelial …
between chemotherapy and immunotherapy as first-line agents in metastatic urothelial …
[PDF][PDF] Atezolizumab in first-line cisplatin–ineligible or platinum-treated locally advanced or metastatic urothelial cancer: long-term efficacy from phase II Study …
AV Balar, R Dreicer, Y Loriot, JL Perez-Gracia… - 2018 - medically.roche.com
BACKGROUND• Cisplatin-based chemotherapy is currently the standard of care in the first-
line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma …
line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma …
Cost-effectiveness of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in the United States
Y Peng, Z She, L Peng, Q Liu, L Yi, X Luo, S Li… - Advances in …, 2021 - Springer
Abstract Introduction The JAVELIN Bladder 100 trial showed that maintenance avelumab
therapy after chemotherapy improved the survival of patients with advanced or metastatic …
therapy after chemotherapy improved the survival of patients with advanced or metastatic …
Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
M Fujiwara, T Yuasa, T Urasaki, Y Komai… - Cancer …, 2021 - Wiley Online Library
Background The paradigm of medical treatment for metastatic urothelial carcinoma is
dramatically changing through the introduction of pembrolizumab. Aim We investigated the …
dramatically changing through the introduction of pembrolizumab. Aim We investigated the …